Conduit Pharmaceuticals Stock Alpha and Beta Analysis
| CDT Stock | 1.09 0.08 7.92% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Conduit Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Conduit Pharmaceuticals over a specified time horizon. Remember, high Conduit Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Conduit Pharmaceuticals' market risk premium analysis include:
Beta (7.28) | Alpha (3.22) | Risk 17.4 | Sharpe Ratio (0.11) | Expected Return (1.99) |
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Conduit |
Conduit Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Conduit Pharmaceuticals market risk premium is the additional return an investor will receive from holding Conduit Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Conduit Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Conduit Pharmaceuticals' performance over market.| α | -3.22 | β | -7.28 |
Conduit Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Conduit Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Conduit Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Conduit Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Conduit Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Conduit Pharmaceuticals shares will generate the highest return on investment. By understating and applying Conduit Pharmaceuticals stock market price indicators, traders can identify Conduit Pharmaceuticals position entry and exit signals to maximize returns.
Conduit Pharmaceuticals Return and Market Media
The median price of Conduit Pharmaceuticals for the period between Sat, Dec 14, 2024 and Fri, Mar 14, 2025 is 4.5 with a coefficient of variation of 70.37. The daily time series for the period is distributed with a sample standard deviation of 3.27, arithmetic mean of 4.64, and mean deviation of 3.02. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Insider Trading | 12/18/2024 |
2 | Acquisition by Fromm Charles of 15700 shares of Conduit Pharmaceuticals at 10.0 subject to Rule 16b-3 | 01/10/2025 |
3 | Student, teacher AI use continued to climb in 2023-24 school year | 01/15/2025 |
4 | Conduit Pharmaceuticals Inc. Announces Reverse Stock Split - The Manila Times | 01/23/2025 |
5 | Conduit Pharmaceuticals Stock Set to Reverse Split on Monday, January 27th | 01/24/2025 |
6 | Conduit Pharmaceuticals Completes Strategic Review with Sarborg to Map Revolutionizing Drug ... | 01/28/2025 |
7 | Disposition of tradable shares by Regan Andrew of Conduit Pharmaceuticals subject to Rule 16b-3 | 02/07/2025 |
8 | Conduit Pharmaceuticals Partners with Charles River in Clinically Relevant Systemic Lupus ... | 02/13/2025 |
9 | Conduit Progresses Phase II of its AI Initiative with Sarborg | 02/20/2025 |
10 | Is Conduit Pharmaceuticals Inc. the Best Micro Cap Stock to Buy Now | 03/07/2025 |
About Conduit Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Conduit or other stocks. Alpha measures the amount that position in Conduit Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2010 | 2024 | 2025 (projected) | Dividend Yield | 0.0294 | 0.0264 | 0.0235 | Price To Sales Ratio | 0.11 | 0.1 | 0.088 |
Conduit Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Conduit Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Conduit Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Conduit Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Conduit Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Conduit Pharmaceuticals' management manipulating its earnings.
| 19th of February 2024 Upcoming Quarterly Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View |
Build Portfolio with Conduit Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Conduit Stock Analysis
When running Conduit Pharmaceuticals' price analysis, check to measure Conduit Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Conduit Pharmaceuticals is operating at the current time. Most of Conduit Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Conduit Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Conduit Pharmaceuticals' price. Additionally, you may evaluate how the addition of Conduit Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.